课题基金 / 基金详情

Analysis of the pathogenesis and identification of candidate genes in familial hemophagocytic lymphohistiocytosis

Analysis of the pathogenesis and identification of candidate genes in familial hemophagocytic lymphohistiocytosis
家族性噬血细胞性淋巴组织细胞增多症发病机制分析及候选基因鉴定
批准号:
14370248
负责人:
ISHII Eiichi
金额:
$8.51万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

ISHII Eiichi的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive disorder occurring in infancy. In our study, clonal proliferation of T lymphocytes has been observed in FHL patients and also various organs of scid mice Cytotoxicity of these T lymphocytes for target cells is usually impaired, consequently, it may be hypothesized that T lymphocytes with cytotoxic defects for target cells will accumulate, proliferate and acquire clonality in FHL. In 1999, perforin gene (PRF1) mutation was identified as a cause of FHL2 subtype. In Japan, the incidence of FHL2 can be calculated as 20-30% of all FHL cases. Furthermore, in 2003, MUNC13-4 mutations were identified in some non-FHL2 patients (FHL3 subtype). We identified several new mutations of MUNC13-4 in FHL, and the incidence of this mutaions was approximately 30% of FHL cases. The difference of phenotypic findings can be observed between FHL2 and FHL3 subtypes. Identification of other genes responsible for remaining cases is therefore a major concern. Althogh it is considered that hematopoietic stem cell transplantation is an only accepted curative therapy for FHL, appropriate diagnosis and decision of appropriate treatment is necessary for FHL patients. In the near future, an entire pathogenesis should be clarified in order to establish appropriate therapies including immunotherapy, stem cell transplantation and gene therapy.
期刊论文(52)
专著(0)
科研奖励(0)
会议论文
Ueda I, Ishii E, Imashuku S, et al.: "Characteristic perform gene mutations of haemophagocytic lymphohistiocytosis patients in Japan."Br J Haematol. 121. 503-510 (2003)
Ueda I、Ishii E、Imashuku S 等人:“日本噬血细胞性淋巴组织细胞增多症患者的基因突变特征。”Br J Haematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yanai F, Ishii E, Yasukawa M, et al.: "Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes : analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells."J Imm
Yanai F、Ishii E、Yasukawa M 等人:“穿孔素在人 CD4 T 淋巴细胞介导的抗原特异性细胞毒性中的重要作用:使用遗传性穿孔素缺陷效应细胞和 Fas 缺陷靶细胞的组合进行分析。”J
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Suga N, Ohga S, Ishii E, et al.: "Perforin defects of primary haemophagocytic lymphohistiocytosis in Japan"Br J Haematol. 116. 346-349 (2002)
Suga N、Ohga S、Ishii E 等人:“日本原发性噬血细胞性淋巴组织细胞增多症的穿孔素缺陷”Br J Haematol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamamoto K, Ishii E, Ohga S, Imashuku S, Sasazuki T, Yasukawa M, et al.: "Identification of novel MUNC13-4 mutations in familial hemophagocytic lymphohistiocytosis and functional analysis of MUNC13-4-deficient cytotoxic T lymphocytes."J Med Genet. (In pre
Yamamoto K、Ishii E、Ohga S、Imashuku S、Sasazuki T、Yasukawa M 等人:“家族性噬血细胞性淋巴组织细胞增多症中新型 MUNC13-4 突变的鉴定以及 MUNC13-4 缺陷型细胞毒性 T 淋巴细胞的功能分析。”J Med
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
26
    Inflammation in rat liver transplantation model
    • 批准号:
      23591881
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2011
    • 负责人:
      ISHII Eiichi
    • 依托单位: